In the long human effort to mend failing joints, technology has always promised to outpace the skilled hand — yet a sweeping British analysis of more than one million hip and knee replacements suggests that robotic precision, for now, does not measurably improve a patient's early odds of avoiding further surgery. Researchers from three universities found that despite costing hospitals millions to adopt and thousands per procedure, robotic-assisted surgery performed no better than conventional methods in reducing the need for repeat operations. The findings arrive as Britain's National Health S
Major study finds robotic hip and knee surgery doesn't reduce repeat surgery risk
New technology should deliver meaningful benefit for patients
Mark
So the robots don't actually help? They cost a million pounds to buy and thousands per surgery, and patients don't do better?
Mimi
Not in the early years, according to this data. The precision is real—the robots do position implants more accurately. But better positioning didn't reduce the overall need for repeat surgery. There was one exception: robotic hip surgery did lower the risk of needing surgery specifically to fix malpositioning problems.
Luke
But that's interesting, right? If robotic surgery prevents malpositioning problems, why doesn't that show up as fewer repeat surgeries overall? What else is causing people to need second operations?
Mimi
Good question. The study looked at early outcomes only—the first few years. Repeat surgery can happen for many reasons: infection, wear, loosening, patient factors. The robots may be solving one problem without solving the others.
Mark
So we don't know yet if they're worth the money?
Luke
We know they're not worth it in the short term, based on this data. But the study itself says longer-term follow-up is needed. Implant survival differences might emerge over time. That's not nothing—it's a genuine unknown.
Mimi
And that's why the NHS is being cautious in a way. They're planning to expand, but not overnight. Sevenfold by 2035 is a gradual increase, not a rush.
Mark
But if the evidence says they don't help, why expand at all?
Luke
Because the evidence doesn't say they don't help—it says they don't reduce early repeat surgery risk. Those are different claims. There could be other benefits: patient satisfaction, surgeon confidence, training value. The study is narrow in what it measures.
Mimi
And the researchers themselves say new technology should deliver meaningful benefit. This study is saying: prove it. Show us the benefit before we spend the money.
Mark
Fair. So what happens next?
Luke
Longer-term studies. If implants last longer with robotic placement, that changes the calculation entirely. If they don't, then the NHS has to decide whether precision for its own sake is worth the cost.
The Pulse
- The largest real-world study of its kind — over one million joint replacements — found robotic surgery offers no early advantage over a surgeon's practiced hand.
- At £1 million per system and up to £2,500 added per procedure, the financial stakes of a planned sevenfold NHS expansion are enormous and now openly contested.
- One narrow signal emerged — robotic hip surgery reduced mispositioning errors — but this precision did not cascade into fewer repeat surgeries overall, exposing a gap between technical gain and patient benefit.
- Researchers used target trial emulation to extract clinical-trial-quality conclusions from registry data, lending the findings unusual methodological credibility.
- The study's horizon is limited to early post-surgical years, leaving open the possibility that implant longevity differences may yet surface — and reshape the entire debate.
In the long human effort to mend failing joints, technology has always promised to outpace the skilled hand — yet a sweeping British analysis of more than one million hip and knee replacements suggests that robotic precision, for now, does not measurably improve a patient's early odds of avoiding further surgery. Researchers from three universities found that despite costing hospitals millions to adopt and thousands per procedure, robotic-assisted surgery performed no better than conventional methods in reducing the need for repeat operations. The findings arrive as Britain's National Health Service prepares to expand robotic surgery sevenfold by 2035, inviting a deeper question that medicine has always faced: when does innovation become wisdom, and when does it remain merely expense?
Three British universities set out to answer a deceptively simple question: does robotic precision actually make joint replacements work better? Drawing on data from more than one million hip and knee procedures recorded in the National Joint Registry between 2018 and 2024, their answer — published in The BMJ — was sobering: no, at least not in the years immediately following surgery.
Robotic systems guide surgeons with computer assistance and mechanical support during implant placement, promising greater accuracy than the human hand alone. The theory is sound — better positioning should mean less wear, fewer complications, and fewer patients returning for revision surgery. But the reality, at scale, told a different story. Neither hip nor knee replacement patients showed meaningful reductions in repeat surgery risk when robotic assistance was used.
There was one narrow exception: robotic hip surgery did reduce the specific risk of complications caused by implant mispositioning. Yet this technical improvement failed to translate into better overall outcomes — a distinction that cuts to the heart of what medical innovation must ultimately deliver.
The findings carry particular weight given the NHS's ambition to expand robotic procedures sevenfold by 2035, with individual systems costing around £1 million to install and adding £1,000 to £2,500 per operation. Lead researcher Hasan Mohammad framed the study as essential independent evidence for a health system on the verge of major commitment: new technology, he argued, must deliver meaningful benefit and genuine value for a publicly funded service.
The researchers employed target trial emulation — a statistical method that makes real-world registry data behave more like a controlled clinical trial — lending their conclusions unusual rigor. Still, the study's window covers only early outcomes, and whether robotic implants prove more durable over decades remains an open and consequential question, one that could yet reframe how aggressively Britain — and health systems worldwide — pursue this costly technological bet.
Three universities in Britain set out to answer a straightforward question: does the precision of robotic technology actually make hip and knee replacements work better? The answer, based on the largest real-world analysis of its kind, is no—at least not in the early years after surgery.
Researchers from Queen Mary University of London, the University of Oxford, and the University of Bristol examined data on more than one million joint replacements recorded in the National Joint Registry between 2018 and 2024. Their findings, published in The BMJ, showed that robotic-assisted surgery did not reduce the overall risk of needing another operation compared with conventional surgery performed by hand. This matters because the technology is expensive, requires substantial hospital investment, and the NHS is planning to dramatically expand its use—aiming to increase robotic procedures sevenfold by 2035.
Robotic systems work by giving surgeons computer guidance and mechanical assistance as they position implants during the operation. The surgeon remains in control throughout, but the technology is meant to place the joint components with greater accuracy than is possible by hand alone. Better positioning should theoretically mean fewer problems down the line: less wear on the implant, fewer complications, and fewer patients needing revision surgery. The systems cost around £1 million to install in a hospital and add between £1,000 and £2,500 to the cost of each individual procedure.
The hip replacement study found no overall reduction in repeat surgery or death rates when robotic assistance was used. There was one narrow finding: robotic hip surgery did lower the risk of needing surgery specifically to fix problems caused by the implant being positioned incorrectly. But this specific benefit did not translate into fewer repeat surgeries overall. The knee replacement study found no difference in repeat surgery risk at all. Both studies looked only at early outcomes—the first few years after surgery—so it remains possible that differences in how long implants last might emerge over longer follow-up.
Hasan Mohammad, an academic clinical lecturer in trauma and orthopedics at Queen Mary and the lead author of the research, framed the findings as a reality check for a health system considering major investment. "This study, which uses novel methodology and represents the largest real-world analysis of its kind worldwide, provides important independent evidence for patients, surgeons and policymakers at a time when robotic hip and knee replacement surgery is being adopted rapidly," he said. "New technology should deliver meaningful benefit for patients and represent good value for a publicly funded health service."
The researchers used a statistical method called target trial emulation to analyze the registry data, a technique designed to make comparisons between groups more closely resemble those of a controlled clinical trial by accounting for differences in patient characteristics. This approach allowed them to draw conclusions from real-world data rather than relying solely on smaller, controlled studies.
The findings arrive at a pivotal moment. Hospitals across Britain are investing in robotic systems, and policymakers are betting that the technology will improve care and efficiency. But this large-scale evidence suggests that greater technical precision in implant placement, while theoretically desirable, does not automatically translate into better outcomes for patients in the short term. Whether longer-term data will reveal advantages remains an open question—one that could reshape how aggressively the NHS pursues robotic expansion.
Notable Quotes
New technology should deliver meaningful benefit for patients and represent good value for a publicly funded health service.— Hasan Mohammad, lead researcher, Queen Mary University of London
Want the full story?
Read the original at Medical Xpress ↗